432 related articles for article (PubMed ID: 34962574)
21. Off spells and dyskinesias: pharmacologic management of motor complications.
Khan TS
Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271
[TBL] [Abstract][Full Text] [Related]
22. Treatment Strategies in Early Parkinson's Disease.
Marsili L; Marconi R; Colosimo C
Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414
[TBL] [Abstract][Full Text] [Related]
23. Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.
Hattori N; Kabata D; Asada S; Kanda T; Nomura T; Shintani A; Mori A
PLoS One; 2023; 18(12):e0269969. PubMed ID: 38134023
[TBL] [Abstract][Full Text] [Related]
24. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.
Stowe R; Ives N; Clarke CE; Handley K; Furmston A; Deane K; van Hilten JJ; Wheatley K; Gray R
Mov Disord; 2011 Mar; 26(4):587-98. PubMed ID: 21370258
[TBL] [Abstract][Full Text] [Related]
26. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
27. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M
Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185
[No Abstract] [Full Text] [Related]
28. Motor fluctuations in Parkinson's disease: pathophysiology and treatment.
Colosimo C; De Michele M
Eur J Neurol; 1999 Jan; 6(1):1-21. PubMed ID: 10209344
[TBL] [Abstract][Full Text] [Related]
29. Medical treatment of Parkinson disease.
Stacy M
Neurol Clin; 2009 Aug; 27(3):605-31, v. PubMed ID: 19555824
[TBL] [Abstract][Full Text] [Related]
30. Management of motor complications in Parkinson's disease.
Dewey RB
Neurology; 2004 Mar; 62(6 Suppl 4):S3-7. PubMed ID: 15037664
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
32. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Lees A
Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
[TBL] [Abstract][Full Text] [Related]
33. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
[TBL] [Abstract][Full Text] [Related]
34. [The treatment of Parkinson's disease].
Baumann CR; Waldvogel D
Praxis (Bern 1994); 2013 Dec; 102(25):1529-35. PubMed ID: 24326048
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
[TBL] [Abstract][Full Text] [Related]
36. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
[TBL] [Abstract][Full Text] [Related]
37. Parkinson's disease. Therapeutic strategies to improve patient function and quality of life.
Danisi F
Geriatrics; 2002 Mar; 57(3):46-50; quiz 52. PubMed ID: 11899548
[TBL] [Abstract][Full Text] [Related]
38. Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.
Laurencin C; Danaila T; Broussolle E; Thobois S
Rev Neurol (Paris); 2016; 172(8-9):512-523. PubMed ID: 27476416
[TBL] [Abstract][Full Text] [Related]
39. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
40. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
